Beverly Hills Private Wealth LLC Has $226,000 Stock Holdings in Bio-Rad Laboratories, Inc. $BIO

Beverly Hills Private Wealth LLC cut its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 938 shares of the medical research company’s stock after selling 75 shares during the quarter. Beverly Hills Private Wealth LLC’s holdings in Bio-Rad Laboratories were worth $226,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BIO. Quarry LP acquired a new stake in shares of Bio-Rad Laboratories in the first quarter valued at $29,000. Allworth Financial LP increased its stake in shares of Bio-Rad Laboratories by 260.0% in the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after buying an additional 104 shares in the last quarter. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after buying an additional 79 shares in the last quarter. Headlands Technologies LLC increased its stake in shares of Bio-Rad Laboratories by 64.1% in the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after buying an additional 139 shares in the last quarter. Finally, Twin Tree Management LP acquired a new stake in shares of Bio-Rad Laboratories in the first quarter valued at $87,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of BIO opened at $331.31 on Wednesday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $387.99. The stock has a market cap of $8.97 billion, a P/E ratio of 28.24 and a beta of 0.97. The stock’s 50-day moving average price is $292.27 and its two-hundred day moving average price is $259.99.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm had revenue of $651.60 million for the quarter, compared to analysts’ expectations of $614.82 million. During the same quarter last year, the business earned $3.11 earnings per share. The company’s revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wells Fargo & Company raised their price target on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Royal Bank Of Canada raised their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bio-Rad Laboratories in a report on Tuesday, October 14th. Finally, Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, August 22nd. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories presently has a consensus rating of “Hold” and a consensus price target of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.